Tarsus Pharmaceuticals is having its best week in months, with the stock up 12% to $70.55 — and the more interesting question is whether the options market's retreat from caution reflects genuine conviction or simply the removal of hedges that have now expired.
The options story has shifted materially since last week's note. The put/call ratio has climbed back to 1.24 from the unusually call-heavy 0.83 reading on July 1 — but it remains well below its 20-day average of 1.63, still about one standard deviation on the call side of normal. That means the extreme bullishness of last week has faded, but options traders have not rotated back to the defensive posture that dominated most of June, when the ratio ran above 1.85 for weeks on end. The borrow market remains completely unrestrictive: availability is at 1,569% of short interest, cost to borrow is under 0.5%, and there is no lending friction for anyone looking to add a short position. Short interest itself is essentially flat on the week — just 0.01% higher, now at 11.9% of free float — having pulled back from a brief peak above 5.19 million shares in late June. The short position is meaningful but not building with conviction in either direction.
The Street is broadly constructive, though analyst data is now dated — the most recent changes reported in February, with Oppenheimer lifting its target to $105 and Guggenheim moving to $90. Goldman Sachs sits at Neutral with a $51 target raised from a year ago; that figure looks stale relative to the stock now trading at $70.55, suggesting Goldman's stance may have evolved since. The consensus mean target of $94 implies roughly 33% upside from current levels, and factor scores tell a strong growth story: EPS momentum ranks in the 96th and 98th percentiles over 30- and 90-day windows respectively. Valuation has re-rated — the PE multiple has compressed by more than 22 points over the past 30 days, a direct consequence of the stock's 19% gain over that period compressing the forward earnings yield. EV/EBITDA has also tightened by about 12 turns. The bull case rests on XDEMVY's trajectory as the only FDA-approved Demodex blepharitis treatment; the bear case points to accumulated operating losses and execution risk in scaling from $183 million in first-year sales toward the multi-year targets embedded in current price targets.
Insider activity from mid-June warrants a brief note. CEO Bobak Azamian sold just over 10,000 shares around $61.50 — roughly $615,000 worth — on June 17, while CFO Jeff Farrow sold $877,000 in shares the day prior, following a stock award on June 15. Director William Link also sold just over $776,000 across two transactions on the same date. The cluster of sales around $61–$62 was a routine post-award disposal pattern rather than a discretionary exit signal, and the stock has since run 14% above those prices. None of these trades carry high significance scores. Institutional holders remain anchored: Deep Track Capital and BlackRock together hold more than 16% of shares, and several specialist healthcare funds — RTW Investments, Paradigm Biocapital, Janus Henderson — have maintained or grown positions through Q1.
The next earnings event lands August 5. History is thin but not encouraging on first-day reactions: the most recent print on June 25 produced a 6.2% one-day decline and a 2.5% five-day loss, while the May print saw a smaller but still negative immediate response. The ORTEX short score has eased modestly over the past week, dropping from 59.4 to 57.8 — a direction that marginally reduces squeeze pressure heading into the event. With the stock having now run 19% in a month, what to watch into August 5 is whether revenue momentum from XDEMVY can absorb the valuation expansion that has already occurred — and whether the options market adds defensive hedges back as the report date approaches.
See the live data behind this article on ORTEX.
Open TARS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Tarsus Pharmaceuticals just handed bears a difficult week, reporting Q1 results that cleared consensus by a wide margin — and doing so into a short interest position that has already been steadily unwinding. The…
